Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPHGet Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totaling 1,100,000 shares, a growth of 148.9% from the August 31st total of 441,900 shares. Approximately 11.4% of the company’s stock are short sold. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 11.4% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $5.00.

Read Our Latest Stock Analysis on Talphera

Talphera Trading Up 0.9%

TLPH stock opened at $0.95 on Friday. The firm has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.55. Talphera has a 12 month low of $0.38 and a 12 month high of $1.20. The company has a market cap of $43.31 million, a price-to-earnings ratio of -2.37 and a beta of 0.03.

Talphera (NASDAQ:TLPHGet Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. As a group, equities analysts forecast that Talphera will post -0.64 earnings per share for the current year.

Talphera Company Profile

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

Featured Articles

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.